JUBLINGREA logo

Jubilant Ingrevia Limited Stock Price

NSEI:JUBLINGREA Community·₹107.7b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 6 Fair Values set on narratives written by author

JUBLINGREA Share Price Performance

₹0
-815.05 (-100.00%)
₹1,150.00
Fair Value
₹0
-815.05 (-100.00%)
Price ₹0

JUBLINGREA Community Narratives

·
Fair Value ₹1.15k 40.8% undervalued intrinsic discount

Rising Green Chemistry Demand Will Reimagine Global Specialty Markets

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
·
Fair Value ₹987.75 31.1% undervalued intrinsic discount

Improved Margins And Board Meeting Will Shape Export Opportunity Outlook

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
·
Fair Value ₹657 3.6% overvalued intrinsic discount

Regulatory Tensions And China+1 Shifts Will Test Recovery Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
₹1.15k
40.8% undervalued intrinsic discount
Revenue
18.68% p.a.
Profit Margin
8.88%
Future PE
39.82x
Price in 2029
₹1.64k
₹657
3.6% overvalued intrinsic discount
Revenue
10.13% p.a.
Profit Margin
8.43%
Future PE
30.88x
Price in 2029
₹942.45

Trending Discussion

Updated Narratives

JUBLINGREA logo

JUBLINGREA: Upcoming Board Meeting And Dividend Decision Will Support Long Term Earnings Visibility

Fair Value: ₹1.15k 40.8% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
JUBLINGREA logo

JUBLINGREA: Upcoming Meetings Will Highlight Risks To Current Optimism

Fair Value: ₹657 3.6% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
JUBLINGREA logo

JUBLINGREA: Solid Revenue Outlook And Profitable Operations Will Boost Future Upside

Fair Value: ₹987.75 31.1% undervalued intrinsic discount
2 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with reasonable growth potential.

0 Risks
1 Reward

Jubilant Ingrevia Limited Key Details

₹43.9b

Revenue

₹27.1b

Cost of Revenue

₹16.8b

Gross Profit

₹14.0b

Other Expenses

₹2.8b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
17.58
38.18%
6.33%
25.0%
View Full Analysis

About JUBLINGREA

Founded
2019
Employees
2139
CEO
Deepak Jain
WebsiteView website
jubilantingrevia.com

Jubilant Ingrevia Limited engages in life science products and solutions in India, the United States, Europe, China and internationally. The company operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions. The Nutrition & Health Solutions segment provides nutrition and health ingredients; and animal and human nutrition health solutions. The Chemical intermediates segment offers acetyls and specialty ethanol. In addition, it provides vitamins, mineral premixes, stress regulator, amino acid, herbal choline, herbal non-antibiotic growth promoter and egg quality enhancer, toxin binder, acidifiers, and enzymes and emulsifiers. The company serves pharmaceutical, nutrition, agrochemical, consumer, and industrial sectors. The company was formerly known as Jubilant LSI Limited and changed its name to Jubilant Ingrevia Limited in October 2020. Jubilant Ingrevia Limited was incorporated in 2019 and is headquartered in Noida, India.

Recent JUBLINGREA News & Updates

Narrative Update Jun 15

JUBLINGREA: Upcoming Board Meeting And Dividend Decision Will Support Long Term Earnings Visibility

Analysts keep the Jubilant Ingrevia price target steady at ₹1,150, citing only marginal updates to the discount rate, revenue growth, profit margin, and future P/E assumptions that are not large enough to shift their overall view. What's in the News A board meeting is scheduled for May 26, 2026, at 11:10 a.m. IST to review the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Narrative Update Jun 01

JUBLINGREA: Upcoming Board Decisions Will Support Confidence In Long Term Earnings Visibility

Analysts have lifted their price target on Jubilant Ingrevia from ₹1,100 to ₹1,150 as they now apply a higher future P/E multiple, along with slightly lower assumptions for the discount rate, revenue growth and profit margin. What's in the News A board meeting is scheduled for May 26, 2026, at 11:10 IST to review audited standalone and consolidated financial results for the quarter and year ended March 31, 2026 (Key Developments).

Recent updates

No updates